A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. [electronic resource]
Producer: 20111109Description: 836-45 p. digitalISSN:- 1524-4733
- Angiogenesis Inhibitors -- economics
- Antibodies, Monoclonal -- economics
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- economics
- Bevacizumab
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Clinical Trials as Topic
- Cost-Benefit Analysis
- Humans
- Lung Neoplasms -- drug therapy
- Markov Chains
- Paclitaxel -- administration & dosage
- Quality-Adjusted Life Years
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.